Astellas Pharma Gmbh

Noritaka Hamada

Ryo Mizoguchi

Noriyuki Kawano

Satoshi Miyamoto

Takashi Sugane

Isao Kinoyama

Takahiko Tobe

Junya Ohmori

Kenichirou Sakamoto

Yuji Awamura

Takenori Kimura

Makoto Kasai

Kuniyuki Sano

Takaaki Sakaida

Yu Iwakawa

Hiroki Okui

Anytime obtained is uniform crystal of N-(4-fluorophenyl)-N'-phenyl-N&#x2033;-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine (compound A) and/or N,N&#x2032;-bis (4-fluorophenyl)-N&#x2033;-(pyrimidin-2-ylmethyl)-1,3,5-triazine-2,4,6-triamine (compound B) as a medicament or a starting material for the preparation of the medicament, and provided are a fumarate of the compound A and/or the compound B having excellent stability and a novel crystal thereof. A salt of the compound A and/or the compound B with fumaric acid enables uniform crystal to be anytime obtained, and thus, it is a compound that is very useful as a medicament or a starting material for the preparation of the medicament having excellent stability.

Salt of 1,3,5-triazine-2,4,6-triamine derivative

Object Provided are &#x3b2;-form crystal, &#x3b3;-form crystal, and &#x3b1;-form crystal of a benzoxadiazole derivative, wherein a uniform crystal having sufficient qualities can be obtained with high reproducibility, and they can be anytime supplied as crystals of drug substance for use in producing pharmaceuticals, are particularly suitable for mass synthesis in industrial production, hardly exhibit hygroscopicity and have particularly excellent photo-resistance. Means for Resolution A solving means includes &#x3b2;-form crystal of 4-[3-isopropyl-5-(6-phenyl-3-pyridyl)-4H-1,2,4-triazol-4-yl]-2,1,3-benzoxadiazole, which shows an endothermic peak at 145 to 150&#xb0; C. according to a differential scanning calorimeter analysis (DSC analysis) and shows X-ray powder diffraction peaks at 9.8, 11.1, 12.8, 13.3, 17.1, 20.2, 21.2 and 22.3 in 2&#x3b8;(&#xb0;), and the like.

Crystals of benzoxadiazole derivative

Growing community of inventors

Tokyo, Japan

Noritaka Hamada